Posted by Michael Wonder on 19 Jul 2022
Genmab announces that AbbVie will submit marketing authorisation application to EMA for epcoritamab for the treatment of relapsed/refractory diffuse large B-cell lymphoma
18 July 2022 - Genmab today announced that AbbVie will submit a conditional marketing authorisation application with the EMA for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, in the second half of 2022.
Genmab recently announced that the company will submit a biologics license application for epcoritamab with the U.S. FDA for the treatment of patients with relapsed/refractory large B-cell lymphoma, also in the second half of 2022.
